We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, 5x7 Color Wood Print USA, during the 2022 mpox emergency; 32.4% received tecovirimat.Treatment rates by race/ethnicity were 38.8% (White), 31.
3% (Black/African American), jumpers 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other).Future public health emergency responses must prioritize institutional and structural racism mitigation.